27 January 2015

Issued: London UK - LSE Announcement

GSK announces that Sir Philip Hampton has been appointed Chairman of the Nominations Committee (the "Committee") with effect from today, replacing Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.

In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee, effective today.

The membership of the Nominations Committee is now:

Committee Chairman Sir Philip Hampton Chairman Designate
Members Sir Christopher Gent Chairman
Professor Sir Roy Anderson Scientific & Medical Expert
Lynn Elsenhans Non Executive Director
Judy Lewent Audit & Risk Committee Chairman
Sir Deryck Maughan Senior Independent Director
Tom de Swaan Remuneration Committee Chairman

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.

distributed by